Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… | Phase 3 | terminated | Feb 7, 2022 | Merck Sharp & Dohme LLC | MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support… | Efficacy / futility |
| NCT06868238 | Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel… | Phase 2 | suspended | Mar 10, 2025 | University of Florida | Major protocol revision involving eligibility criteria and screening procedures in progress | Other (stated, no rule matched) |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Phase 2 | suspended | Aug 28, 2023 | City of Hope Medical Center | Budget Issue | Funding |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | Phase 3 | terminated | May 2, 2014 | ETOP IBCSG Partners Foundation | Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a… | Enrollment / accrual |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2022 | Novartis Pharmaceuticals | The trial was terminated due to a business decision and not as a result of any safety concerns | Safety / toxicity |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… | Phase 1 / Phase 2 | terminated | May 8, 2024 | GlaxoSmithKline | Operational challenges | Other (stated, no rule matched) |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III… | N/A | terminated | Jul 5, 2023 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… | Phase 2 | terminated | Mar 27, 2024 | Memorial Sloan Kettering Cancer Center | Study closed by Amgen due to lack of enrollment | Enrollment / accrual |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 6, 2023 | Roswell Park Cancer Institute | Funding ended | Funding |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Phase 2 | suspended | Jun 10, 2026 | UNC Lineberger Comprehensive Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT04669860 | Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate… | — | suspended | Dec 17, 2020 | University of Miami | lack of funding | Funding |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | N/A | suspended | Dec 14, 2016 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer… | Phase 1 / Phase 2 | terminated | Nov 17, 2020 | Amgen | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not… | Safety / toxicity |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant…(SMAT) | Phase 2 | terminated | Oct 7, 2010 | Association of Urologic Oncology (AUO) | not stated | Not stated |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | Phase 2 | suspended | Apr 26, 2024 | Duke University | Protocol is currently undergoing study design revisions and will re-open after amendment is IRB… | Other (stated, no rule matched) |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | Phase 2 | terminated | Sep 6, 2017 | M.D. Anderson Cancer Center | The study met its prespecified futility criteria during the prespecified interim futility analysis… | Efficacy / futility |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | Phase 1 | terminated | Jul 16, 2020 | Jonsson Comprehensive Cancer Center | slow Accrual | Enrollment / accrual |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck…(RAVINA) | Phase 2 | terminated | Feb 13, 2023 | European Organisation for Research and Treatment of Cancer - EORTC | discontinuation of all ongoing studies involving xevinapant | Other (stated, no rule matched) |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate… | Phase 2 | suspended | Jan 10, 2024 | Mayo Clinic | Pending additional funding. | Funding |
| NCT06315491 | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | terminated | Mar 18, 2024 | Cybrexa Therapeutics | Limited clinical activity | Other (stated, no rule matched) |
| NCT06754215 | Smoking Cessation Intervention Development for Homeless Youth | N/A | terminated | Dec 31, 2024 | Ohio State University Comprehensive Cancer Center | The study did not progress to full completion due to an unanticipated prolonged medical leave of… | Investigator |
| NCT03606070 | Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in…(IMAHTEP) | N/A | terminated | Jul 30, 2018 | Gustave Roussy, Cancer Campus, Grand Paris | Lack of inclusion | Other (stated, no rule matched) |
| NCT04803084 | Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment | — | suspended | Mar 17, 2021 | Laura Kennedy | MRI upgrade | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Jun 28, 2022 | T-ACE Medical Co., Ltd | T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug… | Other (stated, no rule matched) |
| NCT06477003 | Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer(OUSCCMOTORX) | N/A | suspended | Jun 27, 2024 | University of Oklahoma | Administrative reasons. | Other (stated, no rule matched) |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid… | Phase 1 | suspended | Apr 12, 2021 | National Cancer Institute (NCI) | Other - Pending amendment. | Other (stated, no rule matched) |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | Phase 2 | withdrawn | Jun 21, 2022 | Andrei Iagaru | logistical issues | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials